Sesen Bio

Read more
Thomas Cannell's photo - President & CEO of Sesen Bio

President & CEO

Thomas Cannell

CEO Approval Rating

76/100

Founded:

2008

Status:

PublicIndependent CompanyNASDAQSESN

SESEN BIO TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Sesen Bio's company profile
Thomas Cannell's photo - President & CEO of Sesen Bio

Thomas Cannell

President & CEO

76/100
24
$147.5M
$17.8M
View Profile
1
Sesen Bio's Competitor - ADC Therapeutics logo
Chris Martin's photo - Co-Founder & CEO of ADC Therapeutics

Chris Martin

Co-Founder & CEO

89/100
208
$808.7M
$156.7M
View Profile
2
Sesen Bio's Competitor - ADC Bio logo
Alan Raymond's photo - Chairman of ADC Bio

Alan Raymond

Chairman

87/100
38
$5.4M
$4M
View Profile
3
Sesen Bio's Competitor - CytomX logo
Sean A. McCarthy's photo - Chairman & CEO of CytomX

Sean A. McCarthy

Chairman & CEO

91/100
137
$290.6M
$66.4M
View Profile
4
Sesen Bio's Competitor - Aileron Therapeutics logo
Manuel C. Aivado's photo - President & CEO of Aileron Therapeutics

Manuel C. Aivado

President & CEO

88/100
23
$219.1M
$4M
View Profile
5
Sesen Bio's Competitor - bluebird bio logo
Nick Leschly's photo - President & CEO of bluebird bio

Nick Leschly

President & CEO

74/100
764
$526.4M
$50.2M
View Profile
6
Sesen Bio's Competitor - ARIAD logo
Paris Panayiotopoulos's photo - President & CEO of ARIAD

Paris Panayiotopoulos

President & CEO

70/100
459
- -
$186.2M
View Profile
7
Sesen Bio's Competitor - Gradalis logo
David Shanahan's photo - Chairman & CEO of Gradalis

David Shanahan

Chairman & CEO

77/100
35
$67.9M
$4M
View Profile
8
Sesen Bio's Competitor - BioAtla logo
Jay M. Short's photo - Chairman & CEO of BioAtla

Jay M. Short

Chairman & CEO

78/100
36
$162.3M
$ < 1M
View Profile
9
Sesen Bio's Competitor - ImmunGene logo
Sanjay D. Khare's photo - Chairman & CEO of ImmunGene

Sanjay D. Khare

Chairman & CEO

73/100
16
$9.2M
$5M
View Profile
10
Sesen Bio's Competitor - Meditope logo
Stephanie Hsieh's photo - President & CEO of Meditope

Stephanie Hsieh

President & CEO

82/100
30
$7.3M
$9.8M
View Profile
11
Sesen Bio's Competitor - ImmunoGen logo
Mark Enyedy's photo - President & CEO of ImmunoGen

Mark Enyedy

President & CEO

81/100
296
$3M
$136.6M
View Profile
12
Sesen Bio's Competitor - Spark Therapeutics logo
Jeffrey D Marrazzo's photo - Co-Founder & CEO of Spark Therapeutics

Jeffrey D Marrazzo

Co-Founder & CEO

89/100
450
$377.8M
$93.5M
View Profile

Missing a competitor? Contribute!

ADC Therapeutics is a top competitor of Sesen Bio. ADC Therapeutics is a Public company that was founded in 2011 in Epalinges, Vaud. ADC Therapeutics operates in the Biotechnology industry. Compared to Sesen Bio, ADC Therapeutics has 184 more employees.

ADC Bio is seen as one of Sesen Bio's biggest rivals. ADC Bio was founded in 2010, and is headquartered in Chester, England. ADC Bio is in the Biotechnology industry. ADC Bio generates $13.8M less revenue vs. Sesen Bio.

CytomX is seen as one of Sesen Bio's top competitors. CytomX was founded in South San Francisco, California} in 2008. CytomX competes in the Biotechnology industry. Compared to Sesen Bio, CytomX generates $48.6M more revenue.

Sesen Bio Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$17.8M

Sesen Bio's revenue is the ranked 8th among it's top 10 competitors. The top 10 competitors average 55.8M. Over the last three quarters, Sesen Bio's revenue has decreased by 80.1%. Specifically, in Q2 2021's revenue was $2.2M; in Q1 2021, it was $4.3M; in Q3 2020, it was $11.2M.

Sesen Bio Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Viventia Bio Inc.

Sep 2016

Source »
undisclosed
Viventia Bio designs, develops, engineers, and commercializes protein therapeutic technology to identify and address patients with cancers.

These are all the companies that Sesen Bio has acquired. Sesen Bio's latest acquisition was Viventia Bio Inc. in Sep 2016. Viventia Bio designs, develops, engineers, and commercializes protein therapeutic technology to identify and address patients with cancers.

Sesen Bio Funding History

Since Sesen Bio was founded in 2008, it has participated in 7 rounds of funding. In total Sesen Bio has raised $147.5M. Sesen Bio's last funding round was on Mar 2018 for a total of $996.0K

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Mar 2018
$996K
-
Unattributed
Nov 2017
$8M
-
Equity
Sep 2016
$13.5M
-
Equity
Dec 2014
$20M
IPO
Feb 2014
$50M
-

Since Sesen Bio was founded in 2008, it has participated in 7 rounds of funding. In total Sesen Bio has raised $147.5M. Sesen Bio's last funding round was on Mar 2018 for a total of $996.0K

Sesen Bio Investments

No recent investments found related to Sesen Bio

Sesen Bio News

September 14, 2021MarketScreener

October 18, 2021 Filing Deadline in Class Action - Contact Lieff Cabraser

(marketscreener.com) The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class act... See more »
September 7, 2021MarketScreener

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Sesen Bio, Inc. (SESN) Investors to Deadline in Securities Class Action, Encourages Investors with Significant Losses to Contact Firm's Attorneys

(marketscreener.com) SAN FRANCISCO, Sept. 07, 2021 -- Hagens Berman urges Sesen Bio, Inc. investors w... See more »
September 5, 2021MarketScreener

Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sesen To Contact Him Directly To Discuss Their Options

(marketscreener.com) NEW YORK, Sept. 05, 2021 -- Faruqi & Faruqi, LLP, a leading national securities ... See more »
September 4, 2021MarketScreener

Lost Money in Sesen Bio, Inc.?

(marketscreener.com) Gibbs Law Group Investigates Potential Securities Law Violations https://www.mar... See more »
September 3, 2021MarketScreener

October 18, 2021 Filing Deadline in Class Action - Contact Lieff Cabraser

(marketscreener.com) The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class act... See more »
September 2, 2021MarketScreener

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Sesen Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - SESN

(marketscreener.com) WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of th... See more »

Sesen Bio Press Releases

September 17, 2021NewsFile

Berger Montague Investigates Securities Fraud Allegations Against Sesen Bio, Inc. (SESN); Lead Plaintiff Deadline is October 18, 2021

Philadelphia, Pennsylvania--(Newsfile Corp. - September 17, 2021) - Berger Montague is investigating ... See more »
September 14, 2021NewsFile

Berger Montague Investigates Securities Fraud Allegations Against Sesen Bio, Inc. (SESN); Lead Plaintiff Deadline is October 18, 2021

Philadelphia, Pennsylvania--(Newsfile Corp. - September 14, 2021) - Berger Montague is investigating ... See more »
September 3, 2021NewsFile

Sesen Shareholder Notice

New York, New York--(Newsfile Corp. - September 3, 2021) - Faruqi & Faruqi, LLP, a leading national ... See more »
August 29, 2021NewsFile

Sesen Update

New York, New York--(Newsfile Corp. - August 29, 2021) - Faruqi & Faruqi, LLP, a leading national sec... See more »
August 26, 2021NewsFile

Sesen Shareholder Notice

New York, New York--(Newsfile Corp. - August 26, 2021) - Faruqi & Faruqi, LLP, a leading national sec... See more »
August 25, 2021NewsFile

Sesen Shareholder Alert

New York, New York--(Newsfile Corp. - August 25, 2021) - Faruqi & Faruqi, LLP, a leading national sec... See more »
August 24, 2021NewsFile

Sesen Deadline Alert

New York, New York--(Newsfile Corp. - August 24, 2021) - Faruqi & Faruqi, LLP, a leading national se... See more »

Social Media

Sesen Bio Headquarters

245 First Street Suite 1800

Cambridge, Massachusetts02142

617-444-8550

Driving Directions »

Trending Companies

Sesen Bio Summary

ABOUT

Overview

Sesen Bio researches, discovers, develops and commercializes antibody-drug conjugate therapies for the treatment of cancer. Sesen Bio was founded in 2008. Sesen Bio's headquarters is located in Cambridge, Massachusetts, USA 02142. It has raised 147.5M...

CEO

Sesen Bio's President & CEO, Thomas Cannell, currently has an approval rating of 76%. Sesen Bio's primary competitors are ADC Therapeutics, ADC Bio & CytomX.

Frequently Asked Questions about Sesen Bio

  1. When was Sesen Bio founded?

    Sesen Bio was founded in 2008
  2. Who is Sesen Bio's CEO?

    Sesen Bio's CEO is Thomas Cannell
  3. How much revenue does Sesen Bio generate?

    Sesen Bio generates $17.8M in revenue
  4. How much funding does Sesen Bio have?

    Sesen Bio has historically raised $147.5M in funding
  1. Where is Sesen Bio's headquarters?

    Sesen Bio's headquarters is in Cambridge Massachusetts, USA
  2. How many employees does Sesen Bio have?

    Sesen Bio has 24 employees
  3. What sector does Sesen Bio operate in?

    Sesen Bio is in Pharmaceuticals, Biotechnology
  4. Who are Sesen Bio's competitors?

    Sesen Bio's top competitors are ADC Therapeutics, ADC Bio, CytomX